Opinion

Video

Treatment Landscape for Transplant-Eligible Patients with NDMM

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPAAmir Ali, PharmD, BCOP

Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.

Video content above is prompted by the following:

  • Provide a brief overview of first-line treatment options currently available for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Pharmacist talking to a patient with cancer
Related Content
Image Credit: © Nihad - stock.adobe.com
September 28th 2024

Small Molecule Drugs Remain Vital in Addressing Refractory Multiple Myeloma

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Image Credit: © Tatiana Shepeleva - stock.adobe.com
September 28th 2024

Immunotherapy Evolution Continues With Innovative Approaches to Multiple Myeloma Treatment

Alexandra Gerlach, Associate Editor
Image Credit: © Animager - stock.adobe.com
September 27th 2024

Overcoming Treatment Challenges in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapy

Alexandra Gerlach, Associate Editor
Daratumumab Plus Lenalidomide Maintenance in Transplant-Eligible Newly-Diagnosed MM Improves MRD Negativity
September 27th 2024

Daratumumab Plus Lenalidomide Maintenance in Transplant-Eligible Newly-Diagnosed MM Improves MRD Negativity

Aislinn Antrim, Assistant Managing Editor
A vector representation of multiple myeloma cells.
September 27th 2024

Talquetamab-Daratumumab-Pomalidomide Combination Led to Durable Response in Patients With Relapsed/Refractory Multiple Myeloma

Luke Halpern, Assistant Editor